JOSÉ LUIS
GONZÁLEZ LARRIBA
Catedrático de universidad
Institute Catalá Oncología
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institute Catalá Oncología (18)
2024
-
Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612
2023
-
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513
2021
-
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry
PLoS ONE, Vol. 16, Núm. 6 June
2020
-
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Lung Cancer, Vol. 147, pp. 83-90
-
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
Cancer Epidemiology, Vol. 67
2019
-
Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)
Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475
2018
-
First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536
-
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
European Respiratory Journal
-
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38
2010
-
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
-
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
2009
-
Assessing the value of preoperative chemotherapy in early-stage non-small cell lung cancer: mature data and prognostic factors analysis of a Phase III randomized trial of surgery alone vs preoperative Paclitaxel/Carboplatin (PC) vs postoperative PC. Final NATCH data. A Spanish Lung Cancer Group Trial
EJC SUPPLEMENTS
-
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812
-
Recommendations from the Spanish oncology genitourinary group for the treatment of metastatic renal cancer
Cancer Chemotherapy and Pharmacology
2007
-
Cisplatin (CDDP) plus vinorelbine (VRB) as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): molecular correlates
EJC SUPPLEMENTS
-
Elevated levels of thioredoxin (Trx) in serum correlate with poor outcome in docetaxel (doc)/cisplatin (cis)-treated stage IV non-small-cell lung cancer (NSCLC) patients (pts)
EJC SUPPLEMENTS
-
XPD 312 single nucleotide polymorphism (SNP) predicts survival in stage IIIA-B non-sinall-cell lung cancer (NSCLC) patients (pts) < 59 years (y) treated with chemotherapy followed by surgery
EJC SUPPLEMENTS
2005
-
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
Annals of Oncology, Vol. 16, Núm. 7, pp. 1081-1086